We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severeaplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients receivedATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. Ifnecessary, a second course was performed after an interval of one week. All patients achievedclinically significant responses to ATO. The overall complete response rate and overallresponse rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment withATO may be a feasible approach in patients with refractory SAA.
via Journal of Hematology & Oncology
via Journal of Hematology & Oncology
No comments:
Post a Comment